Remove Diabetes Remove Families Remove IT Remove Manufacturing
article thumbnail

How to Get Ozempic & GLP-1’s Covered by Insurance (or Save Big with Plum Health Direct Primary Care): The Ultimate Guide You Can’t Afford to Miss!

Plum Health

Managing diabetes—especially as you get older—can be challenging physically, emotionally, and financially. If you’re living with Type 2 diabetes, you’ve probably heard of Ozempic, Wegovy (semaglutide), Mounjaro or Zepbound (tirzepatide). With Plum Health, managing your diabetes becomes easier, more affordable, and less stressful.

article thumbnail

Maine and Nevada Update Drug Price Transparency Laws

FDA Law

Schlanger — Maine and Nevada previously enacted laws requiring drug manufacturers to report information about the pricing of their products. Both states’ new requirements will become effective in October 2021 and should be considered as manufacturers prepare for state drug price transparency reporting in 2022.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The Best and Worst Cooking Oils for Managing Cholesterol

Imperial Center Family Medicine

In one study , using sesame oil regularly for 90 days significantly improved blood sugar and cholesterol levels in people with diabetes. How Cooking Oils Impact Cholesterol Before getting into specific oils, it helps to know a little about dietary fats and cholesterol. But it adds tremendous flavor and heart-healthy perks.

article thumbnail

Hearing Loss in Geriatrics and Palliative Care: A Podcast with Nick Reed and Meg Wallhagen

GeriPal

Think about the last time you attended a talk on communication skills or goals of care discussions. Was there any mention about the impact that hearing loss has in communication or what we should do about it in clinical practice? I’m guessing not. COVID-19, masks, and hearing difficulty: Perspectives of healthcare providers. Alex: (Singing).

IT 102
article thumbnail

Biased research, aggressive sales, harmful drugs

The Health Policy Exchange

Food and Drug Administration to market a new drug is a critical waypoint along the path to profits for pharmaceutical manufacturers. In the meantime, lobbyists working for the drug manufacturers successfully blocked efforts by Medicare administrators to stop paying for the higher (harmful) doses. Could the FDA and other U.S.